Cargando…
Identifying participants’ preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: an adaptive choice-based conjoint analysis
PURPOSE: There are no recommended treatments for chemotherapy-induced peripheral neuropathy (CIPN) prevention. Recruitment to CIPN prevention clinical trials is challenging because it is difficult to enroll patients between the time of cancer diagnosis and the initiation of neurotoxic chemotherapy....
Autores principales: | Knoerl, Robert, Berry, Donna, Meyerhardt, Jeffrey A., Reyes, Kaitlen, Salehi, Elahe, Thornton, Katherine, Gewandter, Jennifer S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648439/ https://www.ncbi.nlm.nih.gov/pubmed/36355216 http://dx.doi.org/10.1007/s00520-022-07447-y |
Ejemplares similares
-
Exploring the impact of a decision support algorithm to improve clinicians’ chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study
por: Knoerl, Robert, et al.
Publicado: (2021) -
Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors
por: Knoerl, Robert, et al.
Publicado: (2021) -
Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial
por: Knoerl, Robert, et al.
Publicado: (2021) -
What do the data say about chemotherapy-induced peripheral neuropathy assessment and management?
por: Kanzawa-Lee, Grace, et al.
Publicado: (2022) -
Predicted preference conjoint analysis
por: Radas, Sonja, et al.
Publicado: (2021)